Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The goals of this clinical research study are to see how individuals with advanced head and
neck cancer respond to treatment with the new drug thrombospondin (ABT-510) and to learn how
effective it is in destroying cancer cells. The safety of ABT-510 and the effect ABT-510 has
on cells in the body will also be studied.